期刊
JOURNAL OF PROTEOME RESEARCH
卷 18, 期 4, 页码 1679-1690出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.8b00942
关键词
phosphoproteomics; tyrosine kinase; LC-MS; KALIP; kinase substrates
资金
- NIH [5R01GM088317, 1R01GM111788, R01A1098132]
- NSF grant [1506752]
- NIH National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [TL1 TR001107, UL1 TR001108]
- NCI grant [CCSG CA23168]
Ableson tyrosine kinase (ABL) plays essential roles in cell differentiation, division, adhesion, and stress response. However, fusion of the breakpoint cluster region (BCR) to ABL produces constitutive kinase activity that causes chronic myelogenous leukemia (CML). Small molecule tyrosine kinase inhibitors (TKIs) such as imatinib revolutionized the treatment of CML and other cancers, but acquired resistance to these inhibitors is rising. Thus, careful dissection of ABL signaling pathways is needed to find novel drug targets. Here we present a refined proteomic approach for elucidation of direct kinase substrates called kinase assay linked phosphoproteomics (KALIP). Our strategy integrates in vitro kinase assays at both the peptide and protein levels with quantitative tyrosine phosphoproteomics in response to treatment by multiple TKIs. Utilizing multiple TKIs permits elimination of off-target effects of these drugs, and overlapping the in vivo and in vitro data sets allows us to define a list of the most probable kinase substrates. Applying our approach produced a list of 60 ABL substrates, including novel and known proteins. We demonstrate that spleen tyrosine kinase (SYK) is a novel direct substrate of ABL, and we predict our proteomic strategy may facilitate identification of substrates in other cancers that have disrupted kinase signaling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据